Come and see the presentations using MRDR data, and visit us at the Monash University booth in the Exhibition Hall - Booth 119. Please pop by if you have any questions about the registry or to say hi!
| Andrew Spencer | APAC MRDR | Oral | Regional trends in first-line myeloma treatment: Real world results from the Australian & New Zealand and Asia-Pacific Myeloma and Related Diseases Registries | HSANZ - Myeloma | 138 | Mon, Oct 27, 9:30 AM - 9:45 AM |
|
| Ghassan Zammar | ANZ MRDR | Oral | Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real-world evidence of adverse outcomes for high-risk groups | HSANZ - Myeloma | 713 | Tues, Oct 28, 9:45 AM - 10:00 AM |
|
| Jian Li | ANZ MRDR | Oral | New Zealand multiple myeloma patients demonstrate inferior outcomes compared to Australian counterparts – a retrospective cohort study from the Myeloma and Related Diseases Registry |
|
|
||
| Sarah Zhao | ANZ MRDR | Oral | First-line VRd, Rd, and VCd in elderly myeloma patients: Comparison of outcomes using the ANZ Myeloma and Related Diseases Registry | HSANZ - Myeloma | 311 | Mon, Oct 27, 9:15 AM - 9:30 AM |
|
| Jessica Ling | ANZ MRDR | Poster | Outcomes of patients with multiple myeloma post-BCMA directed treatment: an Australian perspective | ||||
| Adam Irving | EpiMAP | Poster | Bortezomib, lenalidomide and dexamethasone versus pre-funding standard of care for newly diagnosed multiple myeloma: a post-market economic evaluation using registry data | HSANZ - Myeloma | 451 |